Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | HF158K1 |
Synonyms | |
Therapy Description |
Limited information is currently available on HF158K1, a putative ERBB2 (HER2)-targeting immunoliposome containing doxorubicin (Jul 2023). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HF158K1 | HF-158K1|HF 158K1 | Limited information is currently available on HF158K1, a putative ERBB2 (HER2)-targeting immunoliposome containing doxorubicin (Jul 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05861895 | Phase I | HF158K1 | A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors | Recruiting | USA | 1 |